190273-89-3

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-2-QUINAZOLINAMINE is used as a building block for the synthesis of various pharmaceuticals. Its high reactivity allows for the creation of new compounds with potential therapeutic properties, contributing to the development of novel drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 6-BROMO-2-QUINAZOLINAMINE is employed as a starting material for the production of agrochemicals. Its reactivity enables the synthesis of compounds with pesticidal or herbicidal properties, enhancing crop protection and yield.
Used in Chemical Research:
6-BROMO-2-QUINAZOLINAMINE is utilized as a reagent in chemical research. Its unique properties make it a valuable tool for studying reaction mechanisms, exploring new synthetic pathways, and advancing the understanding of organic chemistry.
Used in Organic Synthesis:
6-BROMO-2-QUINAZOLINAMINE is used as a starting material for the production of other chemical compounds in the field of organic synthesis. Its versatility and reactivity facilitate the creation of a diverse range of compounds for various applications, including pharmaceuticals, agrochemicals, and other industries.

InChI:InChI=1/C8H6BrN3/c9-6-1-2-7-5(3-6)4-11-8(10)12-7/h1-4H,(H2,10,11,12)

Upstream product

• 124-46-9 guanidine hydrogen carbonate 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 124-46-9 guanidine bis(carbonate) 
• 420-04-2 CYANAMID 
• 29124-57-0 2-amino-5-bromobenzaldehyde 
• 20357-20-4 5-bromo-2-nitrobenzaldehyde 
• 3132-99-8 m-bromobenzoic aldehyde 
• 593-85-1 guanidine carbonate 
• 593-85-1 diguanidine carbonate 

Downstream Products

• 1425503-93-0 6-phenylquinazolin-2-amine 
• 1425503-96-3 C₂₄H₂₂N₄O₂ 
• 1032573-76-4 N-(2-methoxyethyl)-4-[(6-pyridin-3-ylquinazolin-2-yl)amino]benzamide 
• 1032573-61-7 N-(2-methoxyethyl)-4-{[6-(4-methylpyridin-3-yl)quinazolin-2-yl]amino}benzamide 
• 1032573-74-2 N-(2-methoxyethyl)-4-{[6-(6-methoxypyridin-3-yl)quinazolin-2-yl]amino}benzamide 
• 1032573-72-0 4-{[6-(6-fluoropyridin-3-yl)quinazolin-2-yl]amino}-N-(2-methoxyethyl)benzamide 
• 1425503-99-6 C₂₂H₂₀N₆O₂ 
• 1008504-60-6 4-[(6-pyridin-4-ylquinazolin-2-yl)amino]benzaldehyde 

Relevant academic research and scientific papers

Microwave-assisted preparation of fused bicyclic heteroaryl boronates: Application in one-pot suzuki couplings

The rapid and efficient synthesis of various disubstituted 5,6-fused heterocycles using a microwave-assisted one-pot cyclization-Suzuki coupling approach is described. This work highlights the tolerance of the boronic ester functional group to a variety o

INHIBITOR OF BRUTON'S TYROSINE KINASE

Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Futher provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.

TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

Inhibitor of Bruton tyrosine kinase

The invention discloses a compound of a formula (I) with Btk inhibiting activity, wherein all variables are as defined in the description. The compound can be used for treating autoimmune diseases, heteroimmune diseases, cancers or thrombembolia. The inve

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4

Herein, we embarked on a structural optimization campaign aiming at the discovery of second generation anti-angiogenesis agents with our previously reported BPS-7 as lead compound. A library of 27 compounds has been afforded based on the highly conserved ATP-binding pocket of VEGFR-2, Tie-2, and EphB4. Several title compounds exhibited simultaneous inhibitory effects against three angiogenic RTKs. These compounds with a ‘triplet’ inhibition profile have been identified as novel anti-angiogenic and anticancer agents. The representative VDAU11 displayed prominent anti-angiogenic and anticancer potency and could be considered as a candidate for further optimization. These results indicate that N-(pyridin-2-yl)acrylamide could serve as a novel hinge-binding group of triple inhibitors.